Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial-Reference-Cited by-同舟云学术

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

Published:2014-11 Issue: Volume:17 Page:19808
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:Journal of the International AIDS Society

Author:

Fabbiani Massimiliano,Di Giambenedetto Simona,Quiros-Roldan Eugenia,Latini Alessandra,Vullo Vincenzo,Antinori Andrea,Castagna Antonella,Orofino Giancarlo,Francisci Daniela,Grilli Elisabetta,Madeddu Giordanu,Grima Pierfrancesco,Rusconi Stefano,Del Pin Barbara,Mondi Annalisa,Borghetti Alberto,Focà Emanuele,Colafigli Manuela,De Luca Andrea,Cauda Roberto

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.7448/IAS.17.4.19808/fullpdf

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial;PLOS ONE;2019-09-06

2. Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience;Journal of NeuroVirology;2019-01-09

3. Where are we with injectables against HIV infection and what are the remaining challenges?;Expert Review of Anti-infective Therapy;2018-01-25

4. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence;HIV Medicine;2017-07-24

5. Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV ‐1‐infected patients;HIV Medicine;2017-05-15